The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy

Open Access

Peer-reviewed

Research Article

Michael Rosenblum,

Affiliation Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
⨯
Steven G. Deeks,

Affiliation Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
⨯
Mark van der Laan,

Affiliation Division of Biostatistics, School of Public Health, University of California, Berkeley, California, United States of America
⨯
David R. Bangsberg

* E-mail: david_bangsberg@harvard.edu

Affiliation Massachusetts General Hospital Center for Global Health, Harvard Medical School, Harvard Initiative for Global Health, Boston, Massachusetts, United States of America
⨯

x

Viewed

Powered by Altmetric

Questions or concerns about usage data? Please let us know.

Print

Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Viral load
Is the Subject Area "Viral load" applicable to this article?

Thanks for your feedback.
Protease inhibitors
Is the Subject Area "Protease inhibitors" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
HIV infections
Is the Subject Area "HIV infections" applicable to this article?

Thanks for your feedback.